Every material Form 8-K Revvity filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Revvity reported third-quarter 2025 results on October 27, 2025. Revenue rose to $699 million from $684 million, but GAAP EPS fell to $0.40 from $0.77 and adjusted EPS fell to $1.18 from $1.28. The company raised its full-year 2025 adjusted EPS guidance to $4.90 to $5.00 and authorized a new two-year $1 billion share repurchase program.
Q3 revenue was $699 million vs. $684 million a year earlier, up 2% reported and 1% organic.
Q3 adjusted EPS was $1.18 vs. $1.28; GAAP EPS was $0.40 vs. $0.77.
Full-year 2025 adjusted EPS guidance raised to $4.90 to $5.00; revenue guidance updated to $2.83 to $2.88 billion; organic growth guidance of 2% to 4% reaffirmed.
New two-year $1 billion share repurchase program replaces the remainder of the program announced in October 2024.
Revvity's Board appointed Vice President and Controller Anita Gonzales as Vice President and Chief Accounting Officer, effective immediately, on October 23, 2025. She has been the company's controller since May 2023 and joined in March 2021. The filing does not describe any change to her compensation.
Anita Gonzales, 49, appointed Vice President and Chief Accounting Officer on October 23, 2025, effective immediately
She previously served as Vice President and Controller since May 2023 and joined Revvity in March 2021 as Senior Director of Integration and Controllership Initiatives
Prior to Revvity, she spent ten years at General Electric Company, and earlier worked at PricewaterhouseCoopers
She is a Certified Public Accountant with degrees from the University of Texas at Austin
Revvity reported second-quarter 2025 revenue of $720 million, up from $692 million a year earlier, and GAAP EPS of $0.46 versus $0.45. Adjusted EPS from continuing operations fell to $1.18 from $1.22, and the company raised its full-year 2025 revenue guidance to $2.84-$2.88 billion while setting adjusted EPS guidance at $4.85 to $4.95.
Q2 2025 revenue was $720 million, up 4% reported and 3% organic, from $692 million a year earlier.
GAAP EPS was $0.46 versus $0.45; adjusted EPS from continuing operations was $1.18 versus $1.22.
Adjusted operating profit margin was 26.6%, down from 28.8% a year earlier.
Full-year 2025 revenue guidance was raised to $2.84-$2.88 billion, reflecting foreign currency changes; adjusted EPS guidance is $4.85 to $4.95.
Revvity reported first-quarter 2025 revenue of $665 million, up from $650 million a year earlier, and GAAP EPS of $0.35 versus $0.21. Adjusted EPS from continuing operations was $1.01 versus $0.98. The company raised its full-year 2025 revenue guidance to $2.83-$2.87 billion, citing currency changes, and reaffirmed its organic growth and adjusted EPS guidance.
Q1 2025 revenue of $665 million, up 2% reported and 4% organic, versus $650 million a year earlier.
GAAP EPS of $0.35 versus $0.21; adjusted EPS from continuing operations of $1.01 versus $0.98.
Full-year 2025 revenue guidance raised to $2.83-$2.87 billion; organic growth guidance of 3-5% and adjusted EPS guidance of $4.90-$5.00 reaffirmed.
Diagnostics adjusted operating margin fell to 22.8% from 24.3%, while Life Sciences margin rose to 31.1% from 30.0%.
Revvity reported fourth-quarter 2024 revenue of $729 million, up from $696 million a year earlier, and GAAP EPS of $0.78 versus $0.64. For full-year 2024, adjusted EPS from continuing operations rose to $4.90 from $4.65 on revenue that was essentially flat at $2,755 million. The company also initiated 2025 guidance of $2.80-$2.85 billion in revenue and $4.90-$5.00 in adjusted EPS, which gives shareholders its outlook for the year.
Q4 2024 GAAP EPS $0.78 vs $0.64; adjusted EPS from continuing operations $1.42 vs $1.25
Q4 2024 GAAP operating income $119 million vs $77 million; GAAP operating margin 16.3% vs 11.1%
Full-year 2024 GAAP EPS $2.20 vs $5.55 in 2023; the 2023 figure included $4.11 per share from discontinued operations
2025 guidance: total revenue $2.80-$2.85 billion and adjusted EPS $4.90-$5.00
Revvity said preliminary fourth-quarter 2024 revenue growth of about 5% reported and 6% organic, which it expects to produce revenue of about $730 million. It also now expects full-year 2024 adjusted earnings per share to meet or exceed guidance given on November 4, 2024. Full results are due before market open on January 31, 2025.
Q4 2024 reported revenue growth expected at about 5%, organic growth about 6%
Q4 2024 revenue expected at approximately $730 million
Full-year 2024 adjusted EPS expected to meet or exceed the November 4, 2024 guidance
Full Q4 and full-year 2024 results and earnings call on January 31, 2025; CEO Prahlad Singh presents at J.P. Morgan Healthcare Conference on January 13, 2025
Revvity and its subsidiary Revvity Health Sciences entered a new $1.5 billion unsecured revolving credit facility dated January 7, 2025, with Bank of America as administrative agent. The new facility replaces the prior $1.5 billion facility, which was terminated the same day and had been set to run through August 24, 2026; the new one is available through January 7, 2030. As of January 7, 2025, the borrowers had no borrowings and $4.2 million of letters of credit outstanding.
Facility size of $1.5 billion, available through January 7, 2030
Replaces prior $1.5 billion credit agreement dated August 24, 2021, which was terminated January 7, 2025
No borrowings and $4.2 million of letters of credit outstanding as of January 7, 2025
Interest priced at base rate or term SOFR plus a spread tied to Revvity's credit rating
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Revvity filing is on SEC EDGAR ↗. 8-K briefs of other companies →